Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis

Centre Hospitalier Universitaire de Nīmes1 site in 1 country800 target enrollmentMarch 1, 2014

ConditionsAmyotrophic Lateral Sclerosis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Amyotrophic Lateral Sclerosis
Sponsor: Centre Hospitalier Universitaire de Nīmes
Enrollment: 800
Locations: 1
Primary Endpoint: The polymorphisms occurring on a pre-defined set of genes
Status: Completed
Last Updated: 5 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a case-control study performed on a biological collection. The polymorphisms present on a pre-defined list of genes will be studied for 400 Amyotrophic Lateral Sclerosis (sporadic type) DNA samples and 400 control DNA samples.

Registry

clinicaltrials.gov

Start Date

March 1, 2014

End Date

December 31, 2022

Last Updated

5 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Centre Hospitalier Universitaire de Nīmes

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The primary inclusion criterium is the same for that of the parent biological collection, i.e. the patients fulfill requirements for probable or definite Amyotrophic Lateral Sclerosis as defined by revised international criteria (Brooks et al 2000).
•Additionally, included patients were followed-up by doctors at the University Hospital of Montpellier, thus enabling verification of Amyotrophic Lateral Sclerosis criteria over time.

Exclusion Criteria

•The patient has a familial form of Amyotrophic Lateral Sclerosis (autosomic dominant or recessive types) with or without a mutation of one of the 3 genes known to be responsible for familial forms (SOD1, TARDBP, FUS). See Bender (1998).